As of November 2025, the U.S. stock market is experiencing a surge in optimism due to potential resolutions to the prolonged government shutdown, with major indices like the Nasdaq and S&P 500 showing significant gains. In this climate of renewed investor confidence, penny stocks remain a compelling area for exploration, despite their historical reputation for volatility. These smaller or emerging companies can offer unique investment opportunities when they are backed by solid financials and growth potential. We'll explore three penny stocks that stand out for their financial strength and could be appealing options for investors seeking promising opportunities in lesser-known segments of the market.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $1.77 | $387.89M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.68 | $600.36M | ✅ 4 ⚠️ 0 View Analysis > |
| LexinFintech Holdings (LX) | $4.24 | $715.12M | ✅ 4 ⚠️ 2 View Analysis > |
| Global Self Storage (SELF) | $4.96 | $56.46M | ✅ 3 ⚠️ 3 View Analysis > |
| Performance Shipping (PSHG) | $2.15 | $26.73M | ✅ 4 ⚠️ 2 View Analysis > |
| CI&T (CINT) | $4.54 | $594.93M | ✅ 4 ⚠️ 0 View Analysis > |
| Cricut (CRCT) | $4.80 | $1.01B | ✅ 2 ⚠️ 3 View Analysis > |
| VAALCO Energy (EGY) | $3.80 | $412.86M | ✅ 2 ⚠️ 3 View Analysis > |
| BAB (BABB) | $0.889 | $6.4M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.21 | $72.96M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 351 stocks from our US Penny Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
Gold Royalty (GROY)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Gold Royalty Corp. is a precious metals-focused royalty company that offers financing solutions to the metals and mining industry, with a market cap of approximately $582.67 million.
Operations: Gold Royalty Corp. does not have any reported revenue segments.
Market Cap: $582.67M
Gold Royalty Corp. has shown revenue growth, reporting US$4.15 million in Q3 2025, up from US$2.06 million the previous year, although it remains unprofitable with a net loss of US$1.13 million for the quarter. The company is trading at 69% below its estimated fair value and has not significantly diluted shareholders over the past year. While its short-term assets exceed liabilities, long-term liabilities are not covered by short-term assets. Despite being unprofitable, Gold Royalty possesses a sufficient cash runway for more than three years and maintains a satisfactory net debt to equity ratio of 8.1%.
- Click to explore a detailed breakdown of our findings in Gold Royalty's financial health report.
- Review our growth performance report to gain insights into Gold Royalty's future.
Energy Vault Holdings (NRGV)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Energy Vault Holdings, Inc. develops and deploys utility-scale energy storage solutions in the United States, Australia, and internationally with a market cap of approximately $574.59 million.
Operations: The company generates revenue from its Electric Equipment segment, totaling $51.72 million.
Market Cap: $574.59M
Energy Vault Holdings has reported significant revenue growth, with Q3 2025 sales reaching US$33.32 million, up from US$1.2 million a year ago, though it remains unprofitable with an increased net loss of US$26.82 million for the quarter. The company has secured strategic partnerships and agreements, such as a Framework Supply Agreement with EU Green Energy LLC for deploying battery energy storage systems in the Balkans. Despite its high volatility and short-term liabilities exceeding assets, Energy Vault's recent capital raises provide some financial runway as it continues to expand its energy storage solutions globally.
- Get an in-depth perspective on Energy Vault Holdings' performance by reading our balance sheet health report here.
- Learn about Energy Vault Holdings' future growth trajectory here.
Nuvation Bio (NUVB)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapeutic candidates for oncology, with a market cap of approximately $1.59 billion.
Operations: Nuvation Bio generates revenue from its oncology development activities, totaling $26.75 million.
Market Cap: $1.59B
Nuvation Bio has shown significant revenue growth, reporting US$13.12 million for Q3 2025 compared to US$0.727 million a year ago, though it remains unprofitable with a net loss of US$55.79 million for the quarter. The company is advancing its oncology pipeline with ongoing Phase 3 trials and recent regulatory approvals in multiple regions for its ROS1 inhibitor, IBTROZI™ (taletrectinib). Despite high share price volatility and increased debt levels over recent years, Nuvation Bio maintains a strong cash position exceeding total debt and has not significantly diluted shareholders recently.
- Dive into the specifics of Nuvation Bio here with our thorough balance sheet health report.
- Gain insights into Nuvation Bio's future direction by reviewing our growth report.
Turning Ideas Into Actions
- Discover the full array of 351 US Penny Stocks right here.
- Ready To Venture Into Other Investment Styles? Uncover 13 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Gold Royalty might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com